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OBJECTIVES: To compare augmentation episodes for patients with bipolar disorder 
to determine the cost implications of both the augmented and augmenting drug thera-
pies and identify other clinical factors that inﬂuence net medical costs. METHODS: 
A retrospective claims analysis was conducted using data from a US commercial insur-
ance company for bipolar disorder patients aged 18 to 65. Episodes of augmentation 
therapy were identiﬁed in which a second psychotropic medication was added to a 
pre-existing drug regimen and the initial drug was continued for more than 60 days. 
Regression analyses were performed comparing patients on mood stabilizers [MS], 
antipsychotics [AP] or antidepressants [AD] as the initial drug to determine which 
augmented therapy was associated with the lowest cost. An analysis of MS, AP or AD 
as the second (augmenting) drug was conducted to determine which augmentation 
therapy led to the lowest cost. In addition, the effect of 25 clinical variables, including 
related co-morbidities of bipolar disorder were also investigated. RESULTS: A total 
of 62,411 episodes of augmentation therapy were identiﬁed. Post-treatment costs for 
the augmentation episode are signiﬁcantly higher if the augmented drug is an AD 
[$653.19, p = 0.05] or an AP [$2,588.86, p < 0.01] compared to episodes with MS 
as the augmented drug. We found no difference in net medical costs across all three 
classes of augmenting drugs. Most baseline clinical variables were statistically signiﬁ-
cant. However, bipolar depression, anxiety and suicide were not found to be signiﬁ-
cant cost factors in all but the subgroup initially on AD. Additionally, patient aged 
over 35 years contributed signiﬁcantly to cost in all three subgroups. CONCLU-
SIONS: Patients who augment a pre-existing MS drug regimen with either AP or AD 
incur the lowest medical costs. This is consistent with bipolar treatment guidelines 
encouraging MS maintenance therapy with AP or AD augmentations.
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COMPARISON OF COSTS AND HEALTH CARE UTILIZATIONS IN 
PHARMACOTHERAPY, PSYCHOTHERAPY, AND COMBINED THERAPY 
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OBJECTIVES: To compare costs and health care utilizations in pharmacotherapy, 
psychotherapy, and combined therapy groups for treatment of depression. METHODS: 
Depressed individuals 18–65 years were identiﬁed from 1998–2006 Medical Expen-
diture Panel Survey. Individuals with other mental health illnesses were excluded. 
Three mutually exclusive groups were formed: (1) Pharmacotherapy group had at least 
four antidepressant prescriptions yearly and no psychotherapy, (2) Psychotherapy 
group had at least four psychotherapy visits yearly and no antidepressants, (3) Com-
bined therapy group included patients with at least four psychotherapy visits and four 
antidepressants yearly. Yearly mean costs and utilizations were estimated for the three 
groups using generalized linear regression models adjusted for demographics, geo-
graphic diversity, income status, insurance type, perceived mental and physical health 
status, and co-morbidities. RESULTS: Combined therapy group had the highest total 
health care cost ($10610) followed by pharmacotherapy ($7464) and psychotherapy 
groups ($5371), (p-value for differences among the three groups [p] < 0.0001). Mental 
health-related costs for combined therapy, pharmacotherapy and psychotherapy 
groups were $1233, $766 and $516 respectively (p < 0.0001). Ambulatory costs were 
highest for the combined therapy group ($4686) followed by the psychotherapy group 
($3126) and pharmacotherapy group ($2241), (p < 0.0001). Inpatient cost for the 
combined therapy, pharmacotherapy and psychotherapy groups were $2185, $2112, 
and $638, respectively (p = 0.001). Prescription cost was $3451 for combined therapy 
group, $2895 for pharmacotherapy group and $1423 for psychotherapy group (p < 
0.0001). Number of ambulatory visits for combined therapy, pharmacotherapy, and 
psychotherapy groups was 32.24, 11.36, and 22.36, respectively (p < 0.0001). Com-
bined therapy group had the maximum number of prescriptions (42.23), followed 
by the pharmacotherapy group (38.94) and psychotherapy group (17.19), (p < 
0.0001). CONCLUSIONS: Combined therapy group was the highest and psycho-
therapy group was the lowest in terms of costs and utilization for each component 
analyzed. Health decision makers may consider both effectiveness and costs for each 
treatment type.
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OBJECTIVES: To compare changes in total and mental health-related costs after 
initiation of treatment with aripiprazole (ARP) or extended-release quetiapine (QTP 
XR) among patients with bipolar disorder (BD) in managed care plans. METHODS: 
A retrospective cohort study using US claims data assigned adult patients with BD to 
ARP or QTP XR cohorts based on ﬁrst prescription ﬁlled between June 1, 2007 and 
June 30, 2008. The index date was the date of treatment initiation. Patients were 
continuously insured from 6 months before through 6 months after the index date. 
Per-patient changes in total and mental health-related costs over this period were 
compared using Wilcoxon rank-sum tests. RESULTS: A total of 287 patients with BD 
were initiated on QTP XR and 4554 were initiated on ARP. Reductions in total and 
mental health-related costs were greater among patients initiated on QTP XR than 
patients on ARP. Mean per patient reduction in costs for total health-related services 
was $1368 for QTP XR and $8 for ARP (P = 0.0290). Mean mental health-related 
costs were reduced by $1303 with QTP XR compared with an increase of $302 per 
patient (P < 0.001) with ARP. Average per-patient reduction in all-cause hospitaliza-
tion costs was $2577 for QTP XR and $1394 for ARP (P = 0.0064), and the reduction 
in mental health-related hospitalization costs was $2195 for QTP XR and $1038 for 
ARP (P = 0.0028). The increase in average total pharmacy costs was $1229 for QTP 
XR and $1543 for ARP per patient (P = 0.0219). The increase in average mental 
health-related pharmacy costs was $1163 for QTP XR and $1451 for ARP (P < 0.01). 
There were no differences in mean total and mental health-related outpatient costs 
between treatments.CONCLUSIONS: Patients with BD initiated on QTP XR had 
signiﬁcantly greater reductions in mean total and mental health-related costs compared 
with patients initiated on ARP.
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OBJECTIVES: To explore real-world outcomes and costs of patients treated with 
risperidone long-acting injection (RLAI) in New Zealand. METHODS: A mirror-
image retrospective study was conducted comparing outcomes and costs 12 months 
post- versus 12 months pre-initiation of RLAI in adults approved for treatment 
between October 2005-October 2006 in 5 health services. Continuation rates, com-
pulsory treatment status, psychiatric hospitalisation (admission number, bed-stay and 
cost), and treatment data were collected for twelve months on either side of ﬁrst RLAI 
prescription. Hospitalisation costs were valued using estimates for cost/admission and 
cost/bed-day ($NZ, 2009 values). RESULTS: 58.3% of patients remained on RLAI 
12 months after initiation. The average number of admissions for the total study 
population was signiﬁcantly less in the post-RLAI period (1.38 vs 0.61, p < 0.001) 
but average length of bed-stay increased (37.2 vs 53.3 days, p < 0.001) as did com-
pulsory treatment use. Overall bed-nights increased by 6877 in the post-RLAI period 
driven mostly by those who discontinued treatment. Patients who continued RLAI 
had fewer admissions and days in hospital post-RLAI compared to patients who 
discontinued RLAI in the ﬁrst year. The reduction in total hospital admission rates 
between the two treatment periods was signiﬁcantly greater in continuation group and 
mean difference in bed-days between the two treatment periods was signiﬁcantly less 
for continuers (5.4 vs. 31.1 days, p < 0.001). Applying a cost/admission, hospitalisa-
tion costs reduced by approximately $NZ1 million in the post RLAI-period. Applying 
a daily hospitalisation cost resulted in an increase of approximately $NZ3.5 million 
in the post-RLAI period. CONCLUSIONS: study suggests that patients have reduced 
hospital admissions but longer bed-stay after starting RLAI. Longer admissions were 
driven by those that discontinued treatment and continuation was associated with 
improved resource and cost outcomes compared to those who discontinued. These 
ﬁndings have potential implications for payers, providers and patients, requiring 
further investigation over a longer timeframe.
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OBJECTIVES: The annual United States (U.S.) incidence of emergency department 
(ED) staff assaults perpetrated by agitated adult patients with schizophrenia or bipolar 
disorder is difﬁcult to quantify, given staff tendencies toward under-reporting, differ-
ing deﬁnitions of assaultive behaviors, and the broad array of data collection methods 
used. Based on a review of the published literature, we sought to estimate the 1-year 
U.S. incidence and associated costs of patient assaults on ED staff. METHODS: 
Systematic literature review and meta-analysis of published literature from January 1, 
1966-December 31, 2009 using MEDLINE terms: ((“Psychomotor Agitation” OR 
“Aggression”) OR “Violence”) AND “Emergency Service, Hospital” AND 
(English[lang] AND “adult”). “True” annual incidence was calculated as the average 
annualized number of reported assault cases divided by the percent of actual incidence 
represented by these cases. Costs, assessed from the hospital perspective, were calcu-
lated for work days lost by victimized staff. RESULTS: There were 512 publications 
identiﬁed, of which 23 were included. Among an estimated 119 million annual U.S. 
ED visits, patients with schizophrenia or bipolar disorder accounted for 0.8% 
(952,000) and 4–9% (4.8–10.7 million) of visits, respectively. On average, ED nurses 
(N = 31,905) and physicians (N = 17,000) each reported 2.75 and 3.4 annual physical 
assaults (total 145,539) perpetrated by patients. According to staff surveys, approxi-
mately 65% of actual assaults upon staff were unreported. The “true” annual inci-
dence of assaults on ED staff perpetrated by patients with schizophrenia or bipolar 
